U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07847593) titled 'Probiotics in Obese Patients Treated With GLP-1 Receptor Agonists' on Sept. 22.
Brief Summary: This randomized, double-blind, placebo-controlled trial evaluated the effects of a four-strain probiotic formulation in adults with obesity receiving semaglutide. Participants received either the probiotic formulation or placebo, beginning two The primary objective was to determine whether probiotic supplementation reduced gastrointestinal adverse events associated with semaglutide treatment. The primary outcome comprised two complementary measures during the 12-week semaglutide treatment period: the proportion of participants reporting a...